Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Recursion Pharmaceuticals Inc Cl A (NQ: RXRX ) 6.110 +0.050 (+0.83%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Recursion Pharmaceuticals Inc Cl A < Previous 1 2 3 Next > Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 02, 2024 From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability September 03, 2024 REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... From Recursion Pharmaceuticals, Inc. Via GlobeNewswire How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates August 14, 2024 EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT August 08, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th August 05, 2024 Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT From Recursion Pharmaceuticals Via GlobeNewswire How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates August 14, 2024 From FN Media Group LLC Via GlobeNewswire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders August 12, 2024 From Halper Sadeh LLC Via GlobeNewswire CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results August 08, 2024 From Recursion Pharmaceuticals Via GlobeNewswire RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders August 08, 2024 From Halper Sadeh LLC Via Business Wire Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities August 08, 2024 Operational complementarities expected to yield annual synergies of approximately $100 million From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results August 08, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock June 26, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion Announces Proposed Offering of Class A Common Stock June 26, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day June 24, 2024 From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Recursion to Participate in Upcoming Investor Conferences June 03, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool May 29, 2024 Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in... From Recursion Pharmaceuticals Via GlobeNewswire Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board May 24, 2024 Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur From Recursion Pharmaceuticals Via GlobeNewswire The Next Drug You Take May be Designed By A.I. May 14, 2024 Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030 Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results May 09, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 May 02, 2024 Company to host public L(earnings) Call on May 9 at 5:00 pm ET From Recursion Pharmaceuticals Via GlobeNewswire Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry May 13, 2024 BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. From Recursion Pharmaceuticals Via GlobeNewswire Recursion to Participate in Upcoming Investor Conferences May 01, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program April 30, 2024 The grant designates Altitude Lab as a top acceleration program for biotechnology startups From Recursion Pharmaceuticals Via GlobeNewswire Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer April 16, 2024 Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Recursion to Participate in Upcoming Investor Conference April 02, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion Publishes Annual Environmental, Social and Governance Report March 26, 2024 Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact. From Recursion Pharmaceuticals Via GlobeNewswire Recursion Announces Plans to Open New Office in London March 11, 2024 Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the... From Recursion Pharmaceuticals, Inc. Via GlobeNewswire Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community March 01, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion to Participate in Upcoming Investor Conferences March 01, 2024 From Recursion Pharmaceuticals Via GlobeNewswire Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results February 27, 2024 From Recursion Pharmaceuticals Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.